Safety and efficacy of single CHAP Hyaluronan injection versus three injections of linear Hyaluronan in pain relief for knee osteoarthritis: a prospective, 52-week follow-up, randomized, evaluator-blinded study

Huang, Teng-Le; Tsai, Chun-Hao

doi:10.1186/s12891-021-04467-3

Table 2 Observational mean and standard deviation of efficacy-related parameters

From: Safety and efficacy of single CHAP Hyaluronan injection versus three injections of linear Hyaluronan in pain relief for knee osteoarthritis: a prospective, 52-week follow-up, randomized, evaluator-blinded study

	CHAP-HA (N = 71)			Linear-HA (N = 69)			P^b
Variable	Mean	SD	P^a	Mean	SD	P^a	P^b
VAS pain
Baseline	52.90	18.21	–	53.19	13.98	–	0.917
4th week	25.63	18.44	< 0.001^‡	29.65	20.56	< 0.001^‡	0.216
12th week	22.42	18.21	< 0.001^‡	29.39	23.50	< 0.001^‡	0.052
26th week	21.48	21.51	< 0.001^‡	37.04	24.51	< 0.001^‡	< 0.001^‡
39th week	33.31	20.40	< 0.001^‡	48.99	21.94	1.000	< 0.001^‡
52th week	43.10	18.45	0.001^‡	51.45	22.33	1.000	0.012^‡
VAS stiffness
Baseline	42.87	22.56	–	44.78	20.77	–	0.603
4th week	22.61	18.82	< 0.001^‡	28.58	22.08	< 0.001^‡	0.103
12th week	21.52	20.01	< 0.001^‡	26.09	19.11	< 0.001^‡	0.196
26th weeks	25.52	21.60	< 0.001^‡	32.97	24.48	0.023^‡	0.069
39th weeks	36.83	20.93	0.555	39.86	22.88	1.000	0.491
52th weeks	41.48	20.88	1.000	44.57	23.21	1.000	0.479
WOMAC pain
Baseline	7.34	3.69	–	7.17	2.94	–	0.771
4th week	3.96	3.31	< 0.001^‡	3.94	2.49	< 0.001^‡	0.952
12th week	3.49	2.96	< 0.001^‡	3.43	2.30	< 0.001^‡	0.944
26th week	3.14	3.33	< 0.001^‡	4.91	2.96	< 0.001^‡	< 0.001^‡
39th week	4.75	3.47	< 0.001^‡	6.07	3.16	0.360	0.014^‡
52th week	5.96	3.84	0.117	6.84	3.88	1.000	0.126
WOMAC stiffness
Baseline	2.94	1.67	–	3.09	1.47	–	0.592
4th week	1.46	1.30	< 0.001^‡	1.88	1.27	< 0.001^‡	0.061
12th week	1.42	1.23	< 0.001^‡	1.59	1.14	< 0.001^‡	0.454
26th week	1.46	1.36	< 0.001^‡	2.36	1.40	0.020^‡	< 0.001^‡
39th week	1.76	1.53	< 0.001^‡	2.61	1.58	0.544	0.002^‡
52th week	2.59	1.57	1.000	2.83	1.68	1.000	0.477
WOMAC joint function
Baseline	35.52	11.69	–	36.38	10.76	–	0.653
4th week	23.27	10.19	< 0.001^‡	24.83	9.48	< 0.001^‡	0.415
12th week	23.44	10.85	< 0.001^‡	23.52	8.79	< 0.001^‡	0.906
26th week	22.37	11.04	< 0.001^‡	29.99	10.67	0.003^‡	< 0.001^‡
39th week	24.68	11.61	< 0.001^‡	33.54	11.10	1.000	< 0.001^‡
52th week	30.69	12.62	0.030^‡	36.67	12.98	1.000	0.006^‡
WOMAC total score
Baseline	45.80	16.17	–	46.64	14.08	–	0.745
4th week	28.69	13.94	< 0.001^‡	30.65	12.39	< 0.001^‡	0.414
12th week	28.35	14.48	< 0.001^‡	28.55	11.53	< 0.001^‡	0.986
26th week	26.97	15.12	< 0.001^‡	37.26	14.34	< 0.001^‡	< 0.001^‡
39th week	31.18	16.03	< 0.001^‡	42.22	15.05	0.711	< 0.001^‡
52th week	39.24	17.47	0.044^‡	46.33	17.91	1.000	0.016^‡
TUG (second)
Baseline	11.93	3.65	–	11.05	3.03	–	0.120
4th week	10.95	3.27	0.018^‡	9.61	1.99	< 0.001^‡	0.009^‡
12th week	10.37	3.21	< 0.001^‡	9.33	2.13	< 0.001^‡	0.108
26th week	10.42	3.80	0.006^‡	10.30	2.35	0.091	0.372
39th week	10.91	3.83	0.159	10.78	2.22	1.000	0.374
52th week	11.59	4.50	1.000	11.35	2.27	1.000	0.657

VAS: Visual Analogue Scale
WOMAC: Western Ontario and McMaster Universities Arthritis Index
TUG: Timed Up and Go Test
a, corrected P value between post-injections and baseline;
b, P value between groups;
‡, significant, P < 0.05

Back to article page

ISSN: 1471-2474

Contact us

Submission enquiries: bmcmusculoskeletaldisorders@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Musculoskeletal Disorders

Contact us